These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30349254)

  • 1. Involvement of complement activation in the pulmonary vasoactivity of polystyrene nanoparticles in pigs: unique surface properties underlying alternative pathway activation and instant opsonization.
    Mészáros T; Kozma GT; Shimizu T; Miyahara K; Turjeman K; Ishida T; Barenholz Y; Urbanics R; Szebeni J
    Int J Nanomedicine; 2018; 13():6345-6357. PubMed ID: 30349254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complement activation in vitro and reactogenicity of low-molecular weight dextran-coated SPIONs in the pig CARPA model: Correlation with physicochemical features and clinical information.
    Fülöp T; Nemes R; Mészáros T; Urbanics R; Kok RJ; Jackman JA; Cho NJ; Storm G; Szebeni J
    J Control Release; 2018 Jan; 270():268-274. PubMed ID: 29203414
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Features of complement activation-related pseudoallergy to liposomes with different surface charge and PEGylation: comparison of the porcine and rat responses.
    Dézsi L; Fülöp T; Mészáros T; Szénási G; Urbanics R; Vázsonyi C; Őrfi E; Rosivall L; Nemes R; Kok RJ; Metselaar JM; Storm G; Szebeni J
    J Control Release; 2014 Dec; 195():2-10. PubMed ID: 25148822
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A porcine model of complement-mediated infusion reactions to drug carrier nanosystems and other medicines.
    Szebeni J; Bedőcs P; Csukás D; Rosivall L; Bünger R; Urbanics R
    Adv Drug Deliv Rev; 2012 Dec; 64(15):1706-16. PubMed ID: 22820530
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mechanism of nanoparticle-induced hypersensitivity in pigs: complement or not complement?
    Szebeni J
    Drug Discov Today; 2018 Mar; 23(3):487-492. PubMed ID: 29326077
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction.
    Szebeni J; Baranyi L; Savay S; Bodo M; Morse DS; Basta M; Stahl GL; Bünger R; Alving CR
    Am J Physiol Heart Circ Physiol; 2000 Sep; 279(3):H1319-28. PubMed ID: 10993799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complement activation as a bioequivalence issue relevant to the development of generic liposomes and other nanoparticulate drugs.
    Szebeni J; Storm G
    Biochem Biophys Res Commun; 2015 Dec; 468(3):490-7. PubMed ID: 26182876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes. Role of complement and inhibition by soluble CR1 and anti-C5a antibody.
    Szebeni J; Fontana JL; Wassef NM; Mongan PD; Morse DS; Dobbins DE; Stahl GL; Bünger R; Alving CR
    Circulation; 1999 May; 99(17):2302-9. PubMed ID: 10226097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of complement activation-related pseudoallergy in miniature and domestic pigs: foundation of a validatable immune toxicity model.
    Jackman JA; Mészáros T; Fülöp T; Urbanics R; Szebeni J; Cho NJ
    Nanomedicine; 2016 May; 12(4):933-943. PubMed ID: 26767512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A naturally hypersensitive porcine model may help understand the mechanism of COVID-19 mRNA vaccine-induced rare (pseudo) allergic reactions: complement activation as a possible contributing factor.
    Dézsi L; Mészáros T; Kozma G; H-Velkei M; Oláh CZ; Szabó M; Patkó Z; Fülöp T; Hennies M; Szebeni M; Barta BA; Merkely B; Radovits T; Szebeni J
    Geroscience; 2022 Apr; 44(2):597-618. PubMed ID: 35146583
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome.
    Szebeni J; Bedocs P; Rozsnyay Z; Weiszhár Z; Urbanics R; Rosivall L; Cohen R; Garbuzenko O; Báthori G; Tóth M; Bünger R; Barenholz Y
    Nanomedicine; 2012 Feb; 8(2):176-84. PubMed ID: 21704590
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A porcine model of hemodialyzer reactions: roles of complement activation and rinsing back of extracorporeal blood.
    Pethő Á; Piecha D; Mészáros T; Urbanics R; Moore C; Canaud B; Rosivall L; Mollnes TE; Steppan S; Szénási G; Szebeni J; Dézsi L
    Ren Fail; 2021 Dec; 43(1):1609-1620. PubMed ID: 34882053
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles.
    Szebeni J; Alving CR; Rosivall L; Bünger R; Baranyi L; Bedöcs P; Tóth M; Barenholz Y
    J Liposome Res; 2007; 17(2):107-17. PubMed ID: 17613700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A flow cytometric immunoassay to quantify adsorption of complement activation products (iC3b, C3d, SC5b-9) on artificial surfaces.
    Gemmell CH
    J Biomed Mater Res; 1997 Dec; 37(4):474-80. PubMed ID: 9407295
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.
    Szebeni J; Muggia F; Gabizon A; Barenholz Y
    Adv Drug Deliv Rev; 2011 Sep; 63(12):1020-30. PubMed ID: 21787819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Opsonization of yeast cells with equine iC3b, C3b, and IgG.
    Gröndahl G; Johannisson A; Jensen-Waern M; Nilsson Ekdahl K
    Vet Immunol Immunopathol; 2001 Aug; 80(3-4):209-23. PubMed ID: 11457475
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model.
    Szebeni J
    Methods Mol Biol; 2024; 2789():229-243. PubMed ID: 38507008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute physiological changes caused by complement activators and amphotericin B-containing liposomes in mice.
    Őrfi E; Mészáros T; Hennies M; Fülöp T; Dézsi L; Nardocci A; Rosivall L; Hamar P; Neun BW; Dobrovolskaia MA; Szebeni J; Szénási G
    Int J Nanomedicine; 2019; 14():1563-1573. PubMed ID: 30880965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents.
    Szebeni J
    Crit Rev Ther Drug Carrier Syst; 2001; 18(6):567-606. PubMed ID: 11789676
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Formation of complement-activating particles in aqueous solutions of Taxol: possible role in hypersensitivity reactions.
    Szebeni J; Alving CR; Savay S; Barenholz Y; Priev A; Danino D; Talmon Y
    Int Immunopharmacol; 2001 Apr; 1(4):721-35. PubMed ID: 11357884
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.